Taysha Gene Therapies (TSHA) FCF Margin (2023 - 2025)
Taysha Gene Therapies (TSHA) posted FCF Margin of 2263.61% for Q4 2025, down 118.55% sequentially from 1035.75% in Q2 2025, and down 135827.0% YoY from N/an in Q4 2024.
Taysha Gene Therapies (TSHA) FCF Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies has reported FCF Margin for 3 years, with the latest figure at 2263.61% in Q4 2025.
- Quarterly FCF Margin fell 135827.0% year-over-year to 2263.61% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 3523.67% (down 236498.0% YoY) and the FY2025 annual result came in at 1705.96%, down 72674.0% from the prior year.
- FCF Margin eased to 2263.61% in Q4 2025 per TSHA's latest filing, from 1035.75% in the prior quarter.
- Over five years, FCF Margin peaked at 305.94% in Q3 2023 and troughed at 2263.61% in Q4 2025.
- A 3-year average of 1005.02% and a median of 905.34% in 2024 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 92549 bps in 2025, down 135827 bps in 2025.
- Over 3 years, FCF Margin stood at 542.81% in 2023, then sank by 67 bps to 905.34% in 2024, then tumbled by 150 bps to 2263.61% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 2263.61%, 1035.75%, and 957.56% for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,263.61% |
| Jun 30, 2025 | -1,035.75% |
| Mar 31, 2025 | -957.56% |
| Dec 31, 2024 | -905.34% |
| Sep 30, 2024 | -1,205.03% |
| Jun 30, 2024 | -1,961.24% |
| Mar 31, 2024 | -584.52% |
| Dec 31, 2023 | -542.81% |
| Sep 30, 2023 | -305.94% |
| Jun 30, 2023 | -781.59% |
| Mar 31, 2023 | -511.79% |